• Characterization of nr-axSpA patients in clinical practice is lacking in comparison with radiographic axial SpA (radaxSpA).
• Data on how the disease impacts patients health related quality of life (HRQoL) is scarce and comes mainly from randomized clinical trials (RCTs).
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METHODS
RESULTS
The aims of this study were:
• To characterize patients with axial SpA in clinical practice
• To investigate similarities/differences between radiographic and non-radiographic axial SpA with respect to their HRQoL
Main Inclusion Criteria
• Age ≥18 years and able to understand and sign the study informed consent form • Patients were diagnosed as:
Main Exclusion Criteria
• Patient was unable to complete the patient surveys / not able to read and write Swedish
Physician Assessments
• In a first step the physician evaluated whether or not the ASAS criteria to classify axial SpA ( Figure 2 ) were fulfilled • In addition, the physician CRF included information on:
-Patients symptoms such as onset of symptoms -Current diagnosis (ICD-10), -C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR) (to calculate ASDAS) -Joint involvement -Extra-articular manifestations (EAMs) -Imaging performed to diagnose / monitor the disease -Treatment
Patient survey
• The patient survey included information on:
-Patient demographics -Disease activity, function, and satisfaction (BASDAI, ASDAS-CRP, VAS (global and pain), PASS, BASFI, HAQ-S) -Quality of Life (AS-QoL, EQ-5D) More information on the tools/patient reported outcome measures (PROs) can be found in Table 1. The questionnaires were completed by the patient at baseline and at a monthly basis thereafter for 3 months. The current analysis includes the baseline data only.
Statistical Methods
• Descriptive statistics were used to describe the study cohort including validation of the diagnoses (ICD-10), classification of axial SpA, and comparisons between radiographic (rad-axSpA) and non-radiographic axial SpA (nr-axSpA).
• P-values, unadjusted for covariates, were calculated using chisquare tests for categorical variables and t-tests for continuous variables.
• 251 patients were included at baseline. Of those, 197 patients fulfilled the ASAS axial SpA criteria and were included in the study (Figure 3 ).
• Of the 197 axial SpA patients, 63% were characterized as rad-axSpA and 37% as nr-axSpA.
• There were more women in the nr-axSpA group compared with the rad-axSpA group, 50% and 38%, respectively. (Table  2 ) • The nr-axSpA patients had a numerical shorter time between symptom onset and diagnosis (6.7 years vs. 9.0 years), however not significant. (Table 2) • The nr-axSpA patients were diagnosed with AS (35%), other specific inflammatory spondylopathies (31%), inflammatory spondylopathy unspecified (19%), psoriatic spondylitis (11%), and sacroiliitis, not elsewhere classified (4%). (Figure  4) • Data on disease activity and function was not available for all patients (%rad-axSpA/%nr-axSpA); BASDAI (65%/61%), BASFI (65%/61%), VAS-scale data (65%/61%), and ASDAS (58%/57%).
• The nr-axSpA patients showed a significant higher disease burden compared with the rad-axSpA patients, e.g., higher BASDAI (4.1 vs. 2.7), VAS global (4.3 vs. 2.9), VAS pain (4.4 vs. 2.9), and ASDAS(CRP) (2.3 vs. 1.
9). (Figure 5)
• Data on the HAQ-S was available for 81 and 44 of all radaxSpA and nr-axSpA patients, respectively. Information on the PASS for 81 and 43, respectively.
• Mean HAQ-S score at baseline was 0.6 for rad-axSpA and 0.8 for nr-axSpA.
• Of the patients responding to the PASS, 59% of the radaxSpA patients and 44% nr-axSpA patients considered their current disease state to be acceptable.
• EQ-5D data and ASQoL data were collected in 81 and 43 radaxSpA and nr-axSpA patients, respectively.
• Higher scores in the EQ-5D indicate better HRQoL, demonstrating that rad-axSpA patients had a better QoL compared to nr-axSpA patients.
• Mean EQ-5D score at baseline was 0.66 for rad-axSpA and 0.61 for nr-axSpA ( Figure 6 ).
• Higher score in ASQoL indicate worse HRQoL. As with the EQ-5D, nr-axSpA patients reported a lower QoL in the disease specific PRO compared to rad-axSpA patients.
• ASQoL scores was significantly higher in the nr-axSpA group (8.8 vs 6.4, p=0.016; Figure 7)  In this study, from Swedish clinical practice, we included patients from rheumatology clinics with pre-specified diagnoses most likely to be classified as axial SpA.  The results show that nr-axSpA reported a higher impact on HRQoL than patients with rad-axSpA.  In addition, HRQoL is poorer in axial SpA patients compared to the general population.
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STUDY DESIGN & PROCEDURES
• The study was designed as a prospective, cross-sectional, multi-center cohort study in 250 Swedish patients, who were followed for 3 months (Figure 1 ).
• The participating rheumatologist identified patients that met the inclusion/exclusion criteria and invited eligible patients to complete the study survey.
• The physician filled out the CRF once, at baseline.
• Patient provided written informed consent during the initial visit (baseline) prior to the completion of the Clinical Record Form (CRF) and the online patient survey.
• Patients were provided with instructions on how to access the study website to complete the patient survey during the 3 month follow up.
• The study was approved by the Regional Ethics Committee, Karolinska Institutet, Stockholm, Sweden. A 1 -10 scale measuring discomfort, pain, and fatigue (1 being no problem and 10 being the worst problem) in response to six questions on:
(1) Fatigue, (2) Spinal pain, (3) Arthralgia (joint pain) or swelling, (4) Enthesitis, or inflammation of tendons and ligaments (areas of localized tenderness where connective tissues insert into the bone), (5) Morning stiffness duration, (6) Morning stiffness severity The two scores on morning stiffness are averaged to give each symptom equal weighting. Scores of 4 or greater suggest high disease activity.
BASFI
Functional disability
Consists of 10 questions, the first 8 related to functional anatomical limitations and the final 2 to evaluate the patients' ability to cope with everyday life. A visual analogue scale (VAS)(with 0 being "easy" and 10 "impossible) is used to answer the questions on the test. The mean of the ten scales gives the BASFI score -a value between 0 and 10.
ASDAS-CRP Disease activity
Calculated using BASDAI questions 2, 3, and 6, the patient global assessment and CRP concentration. Scores greater than or equal to 2.1 suggest high disease activity
VAS, Global Disease activity
A VAS assessing the patients disease activity during the last week (0 being "none" and 10 "severe").
VAS, pain Disease activity
A VAS assessing the amount of pain the patient had because of his/her condition during the previous week (0 being "no pain" and 10 "worst possible pain").
VAS, nocturnal pain Disease activity
A VAS assessing the amount of back pain during the night that the patient experienced during the previous week (0 being "no pain" and 10 "worst possible pain").
EQ-5D QoL
Contains 5 dimensions: mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. The EQ VAS records the respondent's self-rated health on a vertical VAS where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0).
ASQoL HRQoL
Comprises of 18 dichotomous items that address pain, fatigue, function, and emotion. Score between 0 (best QoL) till 18 (poorest QoL)
PASS Satisfaction
% of patients considering their CURRENT state is satisfactory (when considering all the different ways the disease is affecting them and that they would stay in this state for next few months) Rad-axSpA Nr-axSpA
• Overall, nr-axSpA reported worse QoL compared to another real-life study (Klitz 2012) • Reported values for the nr-axSpA group were close to what was observed in clinical trials (Haibel 2008 ).
STRENGTHS/LIMITATIONS
 A strength with this study was that all patients were clinically assessed by a rheumatologist resulting in a more certain diagnosis as compared to current registry based studies.  Limitations with this study were that: -all patients were recuited at specialized rheumatology centers, which may skew the population towards more severely ill patients, partly explaining the relatively high frequency of AS in the nr-axSPA group. -not all patients completed the patient questionnaire which could result in a skewed patient population.  Although there were some limitations with the study there is a need to characterize these patients since current ICD-10 diagoses are lacking.
